AbbVie Inc.

🇺🇸New York Stock Exchange
Back to all articles
AbbVie Inc. stock analysis ABBV overview
Neutral 0

Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)

- 📈 Piper Sandler analyst David Amsellem reiterated a "Buy" rating on AbbVie with a price target of $299.00.

- 💰 The company reported quarterly revenue of $16.62 billion and net profit of $1.82 billion for the quarter ending December 31.

- 📊 This represents significant growth from last year, which saw $15.1 billion in revenue and a GAAP net loss of $22 million.

- 🧑‍💼 Corporate insider sentiment is currently negative due to increased selling activity among 41 insiders over the past quarter.

- 💸 Specifically, SVP David Ryan Purdue sold 5,230 shares worth approximately $1.22 million earlier this month.

- ⚖️ Other analyst coverage includes a "Buy" from TipRanks and Google's Drug Manufacturers team, though Anthropic maintained a "Hold."

- 👤 Amsellem covers the Healthcare sector with a historical average return of 6.5% and a 50.90% success rate on recommended stocks.

- ⚾ AbbVie was recently named the Official Pharmaceutical Partner of Major League Baseball in a separate announcement.

Bullish Signals
  • Piper Sandler analysts reiterated a 'Buy' rating on AbbVie (ABBV), demonstrating continued institutional confidence in the stock.
  • David Amsellem of Piper Sandler set a price target of $299.00, providing a clear upside potential for investors following his analysis.
  • AbbVie reported strong quarterly revenue of $16.62 billion based on the quarter ending December 31, representing growth from the prior year's $15.1 billion.
  • The company turned its profit situation around significantly, reporting a net profit of $1.82 billion compared to a GAAP net loss of $22 million last year.
  • Amsellem has a historical track record with an average return of 6.5% and a 50.90% success rate on his recommended stocks.
  • AbbVie was recognized as the Official Pharmaceutical Partner of Major League Baseball, expanding its brand visibility and partnerships.
Risk Factors
  • Corporate insider sentiment is negative as over the past quarter, 41 insiders have increased their share sales compared to earlier in the year.
  • David Ryan Purdue, SVP and Controller of AbbVie (ABBV), recently sold 5,230 shares worth $1.22 million, signaling a lack of confidence from top-level executives.
  • AbbVie is facing mixed analyst sentiment, with TipRanks noting that while Piper Sandler maintains a Buy rating, Anthropic has reiterated a Hold rating on the stock.
  • The recent surge in insider selling is explicitly noted as spooking investors, causing the AbbVie stock to slide in price.
Full Analysis
Piper Sandler maintained its Buy rating on AbbVie (ABBV) in a report released on March 27, with analyst David Amsellem setting a price target of $299.00. Amsellem focuses on the Healthcare sector and has a history of recommendations covering stocks such as Amgen and Biogen; TipRanks data indicates his average return is 6.5% with a 50.90% success rate. While AbbVie also received a Buy rating from TipRanks – Google’s Google Drug Manufacturers – General in a report issued the previous day, it was simultaneously reiterated that the company holds a Hold rating from TipRanks – Anthropic on the same date. The analysis of AbbVie is supported by its financial performance for the quarter ending December 31, during which the company reported quarterly revenue of $16.62 billion and a net profit of $1.82 billion. This represents a significant improvement over the prior year, when AbbVie earned revenue of $15.1 billion and recorded a GAAP net loss of $22 million. Despite these positive earnings metrics, broader market sentiment appears cautious due to corporate insider activity, which has been rated negative for the stock over the past quarter due to increased insider selling relative to earlier this year. Specific insider transactions highlight this sentiment; for instance, David Ryan Purdue, SVP and Controller of AbbVie, sold 5,230 shares totaling $1,221,518.80 earlier in the month, marking a notable increase in sell activity among the company's 41 tracked insiders. While Piper Sandler remains bullish, TipRanks aggregates show conflicting analyst opinions on the stock from different firms covering the Drug Manufacturers sector, alongside related headlines noting insider selling spooking investors and AbbVie entering agreements for developing an antibody platform and launching new product indices in aesthetics.